IS5131A - Þíazól bensensúlfonamíð sem ß3 gerandefni fyrir meðhöndlun á sykursýki og offitu - Google Patents

Þíazól bensensúlfonamíð sem ß3 gerandefni fyrir meðhöndlun á sykursýki og offitu

Info

Publication number
IS5131A
IS5131A IS5131A IS5131A IS5131A IS 5131 A IS5131 A IS 5131A IS 5131 A IS5131 A IS 5131A IS 5131 A IS5131 A IS 5131A IS 5131 A IS5131 A IS 5131A
Authority
IS
Iceland
Prior art keywords
benzenesulfonamide
thiazole
obesity
agonist
diabetes
Prior art date
Application number
IS5131A
Other languages
English (en)
Inventor
J. Mathvink Robert
R. Parmee Emma
Tolman Samuel
E. Weber Ann
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9705041.3A external-priority patent/GB9705041D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of IS5131A publication Critical patent/IS5131A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5131A 1997-01-28 1999-07-23 Þíazól bensensúlfonamíð sem ß3 gerandefni fyrir meðhöndlun á sykursýki og offitu IS5131A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3676097P 1997-01-28 1997-01-28
GBGB9705041.3A GB9705041D0 (en) 1997-03-12 1997-03-12 Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity
PCT/US1998/001317 WO1998032753A1 (en) 1997-01-28 1998-01-23 THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Publications (1)

Publication Number Publication Date
IS5131A true IS5131A (is) 1999-07-23

Family

ID=26311166

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5131A IS5131A (is) 1997-01-28 1999-07-23 Þíazól bensensúlfonamíð sem ß3 gerandefni fyrir meðhöndlun á sykursýki og offitu

Country Status (22)

Country Link
EP (1) EP0968209A1 (is)
JP (1) JP2001509166A (is)
KR (1) KR20000070568A (is)
CN (1) CN1251099A (is)
AR (1) AR011092A1 (is)
AU (1) AU728812B2 (is)
BG (1) BG103686A (is)
BR (1) BR9807096A (is)
CA (1) CA2278739A1 (is)
EA (1) EA199900692A1 (is)
EE (1) EE9900328A (is)
HR (1) HRP980044A2 (is)
HU (1) HUP0002053A3 (is)
ID (1) ID22273A (is)
IL (1) IL131130A0 (is)
IS (1) IS5131A (is)
NO (1) NO993646L (is)
PE (1) PE52299A1 (is)
PL (1) PL334833A1 (is)
SK (1) SK100099A3 (is)
TR (1) TR199902442T2 (is)
WO (1) WO1998032753A1 (is)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
EP1741445B1 (en) 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
PT1138685E (pt) 2000-03-31 2004-08-31 Pfizer Prod Inc Processo para a preparacao de piridinas substituidas
IL152528A0 (en) * 2000-07-13 2003-05-29 Lilly Co Eli Beta3 adrenergic agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
IL154928A0 (en) 2000-11-10 2003-10-31 Lilly Co Eli 3-substituted oxindole beta 3 agonists
AU2002221080A1 (en) 2000-12-08 2002-06-18 Masami Kusaka Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
DE60208792T2 (de) * 2001-06-22 2006-08-31 Merck & Co., Inc. Tyrosin-kinase inhibitoren
WO2003016307A1 (en) 2001-08-14 2003-02-27 Eli Lilly And Company β3 ADRENERGIC AGONISTS
EP1444224B1 (en) 2001-08-14 2006-05-03 Eli Lilly And Company 3-substituted oxindole beta-3 agonists
ES2256560T3 (es) * 2001-10-12 2006-07-16 Bayer Pharmaceuticals Corporation Heterociclos de 5 mienbros que contienen nitrogeno sustituidos con felino para el tratamiento de la obesidad.
ATE297925T1 (de) 2001-11-20 2005-07-15 Lilly Co Eli 3-substituierte oxindol beta 3 agonisten
AU2002353844A1 (en) 2001-11-20 2003-06-10 Eli Lilly And Company Beta 3 adrenergic agonists
WO2003059348A1 (en) 2002-01-11 2003-07-24 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
WO2006132196A1 (ja) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β3作動薬を含有する新規な医薬
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007044296A2 (en) * 2005-10-04 2007-04-19 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO1998032753A1 (en) 1998-07-30
HRP980044A2 (en) 1998-10-31
BR9807096A (pt) 2000-04-18
NO993646L (no) 1999-09-27
JP2001509166A (ja) 2001-07-10
EE9900328A (et) 2000-02-15
AU6038498A (en) 1998-08-18
NO993646D0 (no) 1999-07-27
HUP0002053A2 (hu) 2001-08-28
KR20000070568A (ko) 2000-11-25
CN1251099A (zh) 2000-04-19
PE52299A1 (es) 1999-05-26
EP0968209A1 (en) 2000-01-05
ID22273A (id) 1999-09-23
AU728812B2 (en) 2001-01-18
SK100099A3 (en) 2000-05-16
TR199902442T2 (xx) 2000-07-21
HUP0002053A3 (en) 2001-09-28
CA2278739A1 (en) 1998-07-30
AR011092A1 (es) 2000-08-02
PL334833A1 (en) 2000-03-27
BG103686A (bg) 2000-06-30
EA199900692A1 (ru) 2000-02-28
IL131130A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
IS5131A (is) Þíazól bensensúlfonamíð sem ß3 gerandefni fyrir meðhöndlun á sykursýki og offitu
NO964548D0 (no) Substituerte sulfonamider som selektive 3 agonister for behandling av diabetes og fedme
NO20016314D0 (no) Blandinger og fremgangsmåte for oljefeltapplikasjoner
AU3723297A (en) Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
IT1296619B1 (it) Procedimento per il trattamento di protesi a struttura aperturata e relativi dispositivi.
NO993339D0 (no) Fluidblander og tilhörende prosess
ZA953336B (en) Substituted sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
IL158593A0 (en) Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
PT1143977E (pt) Derivados de 2-oxibenzoxazinona para o tratamento da obesidade
IS6303A (is) Notkun retígabíns til meðhöndlunar á taugasjúkdómatengdum sársauka
IS2494B (is) Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni
IS5898A (is) 5HT1 viðtaka gerandefni og metóklópramíð til meðhöndlunar á mígreni
NO983576D0 (no) Brönnbehandlingsfluider og fremgangsmåter
DE69901014D1 (de) Keilantriebsvorrichtung
IS5852A (is) Lyfjamiðlar til meðhöndlunar á parkinsonsveiki ADHD og smákirtilsæxlum
ZA98647B (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
PT1206436E (pt) Retinoides para o tratamento de enfisema
IS5056A (is) Ný meðhöndlun á liðbólgu
DE69503634D1 (de) Struktur zum halten des sprunggelenkes
DK1056448T3 (da) Farmaceutiske kombinationer med tramadol
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
IS5809A (is) Samtíma inngjöf ACAT og MMP tálma til meðhöndlunar á skemmdum vegna fituhrörnunar
DE69925901D1 (de) Hochdruckpumpe oder mischer
FR2839208B1 (fr) Reflecteur d'onde radio et structure comportant le reflecteur d'onde radio monte dessus
NO20013816D0 (no) Benzamidderivater og legemidler som inneholder disse